Bioterrorism: Is it a real threat?

Medical Microbiology and Immunology

Volumn 194, Issue 3, 2005, Pages 109-114

  Gottschalk, René ^a,c   Preiser, Wolfgang ^b  

^a Center of Competence for Highly Infectious Diseases   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Public Health Office   (Germany)

Author keywords

Anthrax; Bioterrorism; Severe acute respiratory syndrome (SARS); Smallpox; West Nile virus

Indexed keywords

ANTHRAX; BIOLOGICAL WARFARE; GENETICS; GOVERNMENT; HEALTH SURVEY; HUMAN; INFECTION CONTROL; MONKEYPOX; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SCIENCE; SEVERE ACUTE RESPIRATORY SYNDROME; SMALLPOX; TERRORISM; VIRUS INFECTION; VIRUS TRANSMISSION;

ANTHRAX; BIOTERRORISM; GENETIC ENGINEERING; HUMANS; MONKEYPOX; MONKEYPOX VIRUS; RESEARCH PERSONNEL; SARS VIRUS; SECURITY MEASURES; SEVERE ACUTE RESPIRATORY SYNDROME; SMALLPOX; SMALLPOX VACCINE; WEST NILE FEVER; WEST NILE VIRUS;

EID: 23944479080     PISSN: 03008584     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00430-004-0228-z     Document Type: Review

References (37)

1. Beeching NJ, Dance DAB, Miller ARO, Spencer RC (2002) Biological warfare and bioterrorism. Br Med J 324:336-339
2. Berger A, Drosten C, Doerr HW, Stürmer M, Preiser W (2004) Severe acute respiratory syndrome (SARS) - paradigm of an emerging viral infection. J Clin Virol. 29:13-22
3. Bravata DM, Sundaram V, McDonald KM, Smith WM, Szeto H, Schleinitz MD, Owens DK (2004) Evaluating detection and diagnostic decision support systems for bioterrorism response. Emerg Infect Dis 10:100-108
4. Bundesministerium für Gesundheit und Soziale Sicherung (BMGS) Pressemitteilung 4/2003. Available at: http://www.bmgs.bund.de/deu/gra/ aktuelles/pm/bmgs03/bmgs4_4340.cfm (accessed 25 May 2004)
5. Bush LM, Abrams BH, Beall A, Johnson CC (2001) Index case of fatal inhalational anthrax due to bioterrorism in the United States. N Engl J Med 345:1607-1610
6. Casadevall A, Pirofski LA (2004) The weapon potential of a microbe. Trends Microbiol 12:259-263
7. Centers for Disease Control and Prevention (1999) Outbreak of West Nile-like viral encephalitis - New York, 1999. MMWR Morb Mortal Wkly Rep 48:845-849
8. Centers for Disease Control and Prevention (2001) Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR Morb Mortal Wkly Rep 50:889-893
9. Centers for Disease Control and Prevention (2003) Bioterrorism Agents/Diseases; last modification November 19, 2003. Available at: http://www.bt.cdc.gov/agent/agentlist-category.asp (accessed 25 May 2004)
10. Centers for Disease Control and Prevention (2003) Smallpox vaccination and adverse reactions: guidance for clinicians. MMWR Morb Mortal Wkly Rep 52:1-28
11. Centers for Disease Control and Prevention (2004) 2003 West Nile virus activity in the United States (reported as of May 21, 2004). Available from http://www.cdc.gov/ncidod/dvbid/west-nile/surv&controlCaseCount03_detailed. htm (accessed 12 July 2004)
12. Di Giulio DB, Eckburg PB (2004) Human monkeypox: an emerging zoonosis. Lancet Infect Dis 4:15-25
13. Dye C, Gay N (2003) Epidemiology: Modeling the SARS epidemic. Science 300:1884-1885
14. Farber NJ, Aboff BM, Weiner J, Davis EB, Boyer EG, Ubel PA (2001) Physicians' willingness to participate in the process of lethal injection for capital punishment. Ann Intern Med 135:884-888
15. Fenner F, Henderson DA, Arita I, Ježek Z, Ladnyi ID (1988) Developments in vaccination and control between 1900 and 1966. In: Smallpox and its eradication, chapter 7. World Health Organization, Geneva
16. Guarner J, Johnson BJ, Paddock CD, Shieh WJ, Goldsmith CS, Reynolds MG, Damon IK, Regnery RL, Zaki SR, the Veterinary Monkeypox Virus Working Group (2004) Monkeypox transmission and pathogenesis in prairie dogs. Emerg Infect Dis 10:426-431
17. Jernigan DB, Raghunathan PL, Bell BP, et al (2002) Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 8:1019-1028
18. Jia XY, Briese T, Jordan I, Rambaut A, Chi HC, Mackenzie JS, Hall RA, Scherret J, Lipkin WI (1999) Genetic analysis of West Nile New York 1999 encephalitis virus. Lancet 354:1971-1972
19. Kelley M, Coghlan J (2003) Mixing bugs and bombs. Bull Atom Sci 59:24-31
20. Lanciotti RS, Roehrig JT, Deubel V, et al (1999) Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 286:2333-2337
21. Ludwig B, Kraus FB, Allwinn R, Doerr HW, Preiser W (2003) Viral zoonoses-a threat under control? Intervirology 46:71-78
22. Monaghan K (2003) SARS down but still a threat. National Intelligence Council Intelligence Community Assessment, August 2003. Available at: http://www.cia.gov/nic/special_sarsthreat.html (accessed 25 May 2004)
23. Müllbacher A, Lobigs M (2001) Creation of killer poxvirus could have been predicted. J Virol 75:8353-8355
24. Nash D, Mostashari F, Fine A, et al (2001) The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 344:1807-1814
25. Petro JB, Plasse TR, Mcnulty JA (2003) Biotechnology: impact on biological warfare and biodefense. Biosecur Bioterror 1:161-168
26. Protocol for the Prohibition of the Use in War of Asphyxiating, Poisonous, or other Gases, and of Bacteriological Methods of Warfare (Geneva Protocol, 1925). Opened for signature: 17 June 1925, entered into force: 8 February 1928. Available at: http://www.sussex.ac.uk/spru/hsp/Genev-Prot.html (accessed 21 June 2004)
27. Reed KD, Melski JW, Graham MB, et al (2004) The detection of monkeypox in humans in the Western hemisphere. N Engl J Med. 350:342-350
28. Richardson L (2004) Buying biosafety - is the price right? N Engl J Med 350:2121-2123
29. Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM (2002) Public health assessment of potential biological terrorism agents. Emerg Infect Dis 8:225-230
30. Rumyantsev SN (2004) The best defence against bioweapons has already been invented by evolution. Infect Genet Evol 4:159-166
31. Spencer RC, Lightfoot NF (2001) Preparedness and response to bioterrorism. J Infect 43:104-110
32. Takahashi H, Keim P, Kaufmann AF, Keys C, Smith KL, Taniguchi K, Inouye S, Kurata T (2004) Bacillus anthracis incident, Kameido, Tokyo, 1993. Emerg Infect Dis 10:117-120
33. The European Agency for the Evaluation of Medicinal Products (2002) EMEA/CPMP guidance document on use of medicinal products for treatment and prophylaxis of biological agents that might be used as weapons of bioterrorism. CPMP/4048/01. Available at: http://www.emea.eu.int/htms/human/bioterror/ bioterror.htm (accessed 18 July 2004)
34. Wirtz A, Gottschalk R, Weber HJ (2003) Management of an attack with biological agents. Reflections on the necessary infrastructure for states and towns. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 46:1001-1009
35. World Health Organization (2002) Smallpox eradication: destruction of variola virus stocks. Report by the Secretariat. Available at: http://www.who.int/gb/ebwha/pdf_files/WHA55/ea5521.pdf (accessed 25 May 2004)
36. World Health Organization (2003) Laboratory safety manual. Second edition (revised). WHO/CDS/CSR/LYO/2003.4. Interim guidelines. World Health Organization, Geneva 2003
37. World Health Organization (2004) Public health response to biological and chemical weapons: WHO guidance, 2nd edn. World Health Organization, Geneva 2004. Available at: http://www.who.int/csr/delibepidemics/biochemguide/en/ (accessed 18 July 2004)